



AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4349

TITLE: "Use of Cytokines to Prevent Breast Cancer Growth and Progression"

PRINCIPAL INVESTIGATOR: Philip M. Grimley, M.D.  
Rockville, MD 20852

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation for the  
Advancement of Military Medicine

REPORT DATE: 08-31-95

TYPE OF REPORT: Annual

19951207 050

PREPARED FOR: U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 1

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE 08-31-95	3. REPORT TYPE AND DATES COVERED Annual 1 Aug 94 - 31 Jul 95
4. TITLE AND SUBTITLE Use of Cytokines to Prevent Breast Cancer Growth and Progression		5. FUNDING NUMBERS DAMD17-94-J-4349
6. AUTHOR(S) Dr. Philip M. Grimley		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Henry M. Jackson Foundation for the Advancement of Military Medicine Rockville, Maryland 20852		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION/AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

This project aims to characterize a novel transcriptional knock out polypeptide (TKO) which we identified in breast cancer cells and which competitively interrupts molecular events in the ISGF3 signaling pathway for interferons- $\alpha/\beta$  (IFN $\alpha$ ). The TKO action is of clinical significance since IFNs- $\alpha/\beta$  are antiproliferative cytokines with significant potential for therapy of stage II or disseminated breast cancer. Improved chromatographic purification of TKO has been achieved during the initial phase of this project and a single polypeptide of ca. 20 kDa associated with ISGF3 DNA-binding inhibition resolved by two dimensional gel electrophoresis. Biochemical sequence analysis and accumulation of purified TKO product for antibody production is progressing. A second objective of this project has been to explore the interaction of the IFN- $\alpha/\beta$  signal cascade and the growth stimulatory signal cascade of prolactin (PRL). These molecular cascades can intersect at the level of transductional protein (STAT1, STAT2 or STAT5) phosphorylation. In pilot testing of three cell lines from human breast carcinomas, differences in STAT1 phosphorylation by PRL and IFN- $\alpha$  correlated inversely to the level of original tumor differentiation: least effects of PRL and maximum effects of IFN- $\alpha$  occurred in a cell line negative for estrogen receptors or other differentiation markers.

14. SUBJECT TERMS Interferon therapy; Transcriptional Knockout; JAK/STAT tyrosine phosphorylation; Prolactin Breast Cancer	15. NUMBER OF PAGES 13
16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified
19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).


✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS CRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

  
PI - Signature

8/23/95  
Date

## **TABLE OF CONTENTS**

	<b>Page #</b>
Front Cover	1
SF 298 - Report Documentation	2
Foreword	3
Table of Contents	4
Introduction	5
Body	6 - 8
Conclusions	9
References	9 - 11
Appendix	12 - 13

(5) INTRODUCTION: Treatment decisions for patients with disseminated breast cancer often pose a difficult problem for oncologists due to the morbidity associated with conventional cytotoxic agents. Many of the conventional cytotoxic agents, such as adriamycin, are mutagenic and increase the risk for subsequent development of leukemia (1). Cytotoxic chemotherapy for stage II breast cancer can be particularly onerous when the cancer is negative for estrogen receptors and the patient is under age 50 years. Interferons (IFNs) are natural cytokines with antiproliferative properties. IFNs- $\alpha/\beta$  can prevent entry of cancer cells into S-phase of the cell-division cycle (2) and act to cause cell differentiation (3-5). Potential benefits of antiproliferative IFN therapy include the avoidance of damage to normal non-proliferating tissues, mitigation of side-effects upon normal proliferating tissues and elimination of the hazard of delayed carcinogenicity. IFN- $\alpha$  has been tested repeatedly in preclinical models (6-8) and phase I/II clinical trials (7-9) and is including adjuvant therapy in some protocols (10, 11).

We have obtained original evidence that the signal transduction pathway for IFN- $\alpha$  can be selectively interrupted in malignant cells by a negative regulator of transcriptional activation (12). This negative regulator was tentatively identified as a polypeptide with a molecular weight of ca. 20 kDa and was designated as *transcriptional knock out* factor or TKO (12). The negative regulatory mechanism of TKO action has been explored and related to inhibition of DNA binding by an auxiliary subunit (48 kDa polypeptide) integral to the IFN- $\alpha$  transcriptional complex (12, 13): the holocomplex (ISGF3) is comprised of two major subunits including ISGF3 $\alpha$  (STAT1 and STAT2) and ISGF3 $\gamma$  (48 kDa polypeptide). The auxiliary 48 kDa subunit is common to a family of IFN regulatory factors (IRF) which include a DNA-binding tumor suppressor protein IRF1 and an oncoprotein IRF2 (14).

TKO activity is detected in cell extracts by using electrophoretic mobility gel shift assays (EMSA) with specific oligonucleotide probes representing a highly conserved enhancer region of IFN-stimulated early genes. This region is the *interferon-sensitive response element (ISRE)*. In preliminary tests, significant TKO activity was identified in two lines of human cells originating from malignant breast lesions. One important purpose of the present work has been to develop the technical capacity to screen patient samples for TKO activity. Identification of TKO in human breast cancers is a potential therapeutic variable and prognostic indicator. While TKO activity can be tested directly in EMSA assays of fresh tissue samples, this approach is practically constrained by sample size, gross uncertainties in sampling of early cancerous lesions and diagnostic imperatives restricting the volume of appropriate tissue available for destructive analysis. A more useful approach will be to develop specific antibodies to the TKO polypeptide, so that properly identified malignant cells in tissue sections can be analyzed for TKO content. Antibody development is a major technical objective of the current project and is being pursued with chromatographic and two dimensional electrophoretic purification of the TKO polypeptide. Twin goals are protein sequence analysis and animal injections of highly purified natural material or appropriate oligopeptides to obtain monospecific or polyclonal TKO antibodies. It is anticipated that the latter will be suitable for studies of frozen biopsy sections, deparaffinized samples of embedded surgical biopsies, or aspiration cytology samples. Success of this work is dependent upon obtaining substantial quantities of highly purified TKO polypeptide(s) and our progress in this direction is described below.

In molecular biologic studies of IFN- $\alpha$  and IFN-gamma signal transduction pathways (15, 16), it has been shown that a critical primary event is phosphorylation of one or more of a family of STAT proteins (signal transducers and activators of transcriptions). The STAT phosphorylation is mediated by particular protein tyrosine kinases (JAK or Tyk) which may autophosphorylate following ligand/receptor binding. The use of polypeptide molecules in the JAK/STAT pathway for signal transduction is common to a number of cytokines in the interleukin family (17), and paradoxically to the polypeptide hormone, prolactin (PRL) (18-21). PRL is one of the principal mammotrophic growth promoters and is a known tumor promoter of the rodent mammary gland (22, 23). We have therefore hypothesized that endogenous PRL could be exercising some role in determining the response of breast cancer cells to IFN- $\alpha$  therapy. An independent objective of the present work has been to explore the possible interactions of PRL and IFN- $\alpha$  during signal transduction. Selective interaction of the phosphorylated 91 kDa STAT protein (STAT1) with an auxiliary polypeptide subunit is key to IFN- $\alpha$  signal specificity, and one aim of the current project is to effect signal modulations which may possibly enhance the antiproliferative activity. Thus, the common roles of JAK and STAT signaling elements in the signal transduction pathways of PRL and IFN- $\alpha$  and their biologic impact at the level of malignant cell proliferation are under investigation. This work involves basic molecular biologic analyses using techniques of gel electrophoresis, immunoblotting and detection of changes in JAK/STAT protein phosphorylation under varied conditions of cell exposures. PRL and IFN- $\alpha$  interactions are being quantitated by EMSA with [ $^{32}$ P]-oligonucleotide probes representing the ISRE or the gamma response region (GRR) enhancer elements of genes stimulated by IFN- $\alpha$  (ISRE and GRR) or PRL (GRR only). Proliferation status of the cells is being monitored by cell cycle analyses, including flow cytometric analyses and immunoblot analyses of Rb phosphorylation, cyclin E and cyclin-dependent CDK or CDC kinase activities.

#### (6) BODY:

Progress in TKO purification: Since initiation of the project, the purification of protein with TKO activity has been refined under the direction of Dr. E. Petricoin and samples have been made available for peptide mapping and amino acid sequence analyses in a collaborating laboratory of Dr. Donald Hunt at the University of Virginia Department of Chemistry. In the original work cell extracts were chromatographically separated at 4°C using heparin-sepharose (Pharmacia) with a 0 to 0.3 M NaCl gradient and hydroxylapatite (Bio-Rad) with a 0-0.3 M Na<sub>2</sub>PO<sub>4</sub> (pH 7.0) elution gradient (12). These procedures have been substantially improved during the initial phase of this project. Currently, cells are dounce homogenized in Buffer A (20 mM KCL; 10 mM HEPES @ pH7; 5 mM dithiothreitol) with 20% glycerol and 0.1% NP40. Cytoplasmic extract is obtained by centrifugation of the whole cell lysate as ca. 8000 x G (10000 rpm) for 30 min. The supernatant is loaded over a heparin-sepharose resin. The flow-through and two column washes are collected and pooled, then loaded onto a hydroxylapatite column. The active fraction elutes in a 0.2-0.4 M sodium phosphate gradient. It is brought to 35% ammonium sulfate final concentration and spun at 8000 x G for 30 minutes. A detergent layer from the top of the tube is collected. This material is further purified by loading onto a phenyl-Sepharose hydrophobic interaction column equilibrated with 35% ammonium sulfate/Buffer A without detergent. The flow-through material then is collected and



applied to a T-butyl hydrophobic interaction C column at 35% ammonium sulfate. This further eliminates non-specific proteins before final concentration on an hydroxylapatite column. Fig. 1 shows TKO activity in a series of fractions eluted from the hydroxylapatite column used in the final purification step. Specific activity, shown by competitive inhibition of complex formation in the EMSA for interferon-induced ISGF3 was increased  $> 10^4$  X based upon relative protein concentrations in crude and purified extracts (not shown).

As shown in Fig. 1, C33a human cervical carcinoma cells grown in suspension cultures provide a practical and standard source of TKO protein for large scale purification. The presence of a TKO activity in crude cytoplasmic extracts from certain breast cancer cell lines was indicated in preliminary experiments for this project. Since initiation of this project, we have been able to purify the active TKO fraction from ZR 75-1 breast cancer cells. The latter cells originated from a case of disseminated infiltrating ductal carcinoma with malignant ascites (24). Comparison of TKO activity from ZR 75-1 whole cell extracts and from the C33a cells is shown in Fig. 2. The sample in lane #3 of Fig. 2 represents a maximally purified fraction from ZR 75-1. Electrophoretic mobility of the polypeptide(s) with TKO activity in the ZR-75-1 breast cancer cells and C33a was compared by two dimensional gel electrophoresis (2D-gels) of the most highly purified extracts eluted from the chromatographic matrices as described above. Figs. 3 represents 2D-gels of these highly purified whole cell extracts stained with silver nitrate (3A from C33a, 3B from ZR-75-1). Despite the exhaustive chromatographic purification described above approximately a dozen clearly delineated polypeptide spots were resolved (Fig. 3). In order to distinguish the spot(s) with specific TKO activity, proteins were depleted by ligation to a synthetic N-terminal fragment (125 AA) of ISGF3 $\gamma$  (48 kDa IRF-family polypeptide) conjugated to sepharose-glutathione beads. The ISGF3 $\gamma$  fragment was amplified from cDNA in E.coli PGEX in a frame for the GST fusion protein. It was extracted by lysis and sonication of E.Coli in PBS with PMSF and 0.1% triton-X 100. Beads were loaded for 2 hr at 4°C in a 50% slurry, thoroughly washed X 2 at 8000 x g in PBS-triton-X, and stored on ice. Just before use the loaded beads were washed in ice cold buffer A and mixed as a 50% slurry with TKO-enriched samples of purified whole cell extract that had been eluted from the final hydroxylapatite column and dialyzed against buffer A. After reaction at 4°C overnight, with continuous agitation, the beads were sedimented at 8000 x g and samples of the supernatant were analyzed on to 2D-gels. A spot indicated by the arrows in Fig. 3 was found to be significantly diminished in intensity after silver or Coomassie blue staining (not shown) while other spots were relatively unaffected. Parallel gel shifts showed that the supernatant had lost the competitive inhibitory activity for DNA binding by ISGF3. A resolved product at ca. 20 kDa therefore has tentatively been identified as the TKO and corresponding samples from preparative 2-D gels have been sent to Dr. Donald Hunt at the University of Virginia in Charlottesville for amino acid sequence analyses.

Pilot analyses of interaction of PRL and IFN- $\alpha$  on JAK/STAT signaling in human breast cancer cells. Three PRL-responsive human breast carcinoma lines (T47D, MCF-7 and BT-20) were tested for PRL and IFN- $\alpha$ -induced signaling via STAT1 and STAT2. Cell dependent effects were noted: in T47D cells PRL and IFN- $\alpha$  induced comparable STAT1 tyrosine phosphorylation responses as determined by phosphotyrosine immunoblotting. The effect of PRL proved additive

to that of IFN- $\alpha$ . In MCF-7 cells PRL, but not IFN- $\alpha$  induced early STAT1 tyrosine phosphorylation. In estrogen-receptor-negative and morphologically less differentiated BT-20 cells, IFN- $\alpha$  induced marked phosphorylation of STAT1 and STAT2, whereas PRL had only a minimal effect on STAT1. Pretreatment of T47D or MCF-7 cells with IFN- $\gamma$  for 24 hr served to enhance the PRL effect on phosphorylation of STAT1, possibly due to stimulation of JAK2 phosphorylation.

Fig. 1 TKO activity in human C33a cell extract indicated by competitive inhibition in EMSA of human fibroblast ISGF3 binding to a  $^{32}\text{P}$ -end labeled double stranded synthetic oligonucleotide with the sequence 5'GATCCATGCCTCGGGAAAGGGAAACCGAAACTGAAGCC3' which corresponds to the interferon sensitive response element (ISRE) from the ISG15 promoter. In this competitive binding assay, a series of fractions of cytoplasmic extract from whole cell lysate eluted from an hydroxylapatite column with a sodium phosphate gradient were tested and compared to negative control samples which show maximum gel retardation of  $^{32}\text{P}$ -oligonucleotide probe by induced ISGF3: sample "HF" (lane #1) was a crude cytoplasmic extract of human fibroblasts after treatment with IFN- $\alpha$  (i.e. positive for ISGF3) and shows gel retardation of the  $^{32}\text{P}$  probe (arrow). The sample "C33" (lane #2) is a known inactive fraction of hydroxylapatite eluate from C33a whole cell extract. Sample TKO (lane #3) is a known positive control sample from a frozen aliquot of highly purified TKO to show maximum competitive inhibition of the ISGF3 gel shift. Note a sharp peak of competitive inhibitory activity in the eluate beginning at lane #7 from the right and tailing of the activity in samples of fractions applied to lanes #10 and #11.

Fig. 2 TKO activity in a human breast cancer cell (ZR-75-1) extract indicated by competitive inhibition in an EMSA representing human fibroblast ISGF3 binding to a  $^{32}\text{P}$ -end labeled double stranded synthetic oligonucleotide probe corresponding to the ISRE from the ISG15 promoter (same as Fig. 1). The sample "HF" in lane #1 was crude extract from human fibroblasts treated with IFN- $\alpha$  and shows the maximum gel retardation of  $^{32}\text{P}$ -oligonucleotide probe by IFN-induced ISGF3. The sample "ZR" in lane #3 is a fraction of sodium phosphate eluate from an hydroxylapatite column with peak competitive inhibitory binding activity in the EMSA assay (similar to lanes #7-9 in Fig. 1) It should be compared to the inhibitory activity evident in sample C33 (lane #2) which comes from a highly purified C33a extract. The sample "HeLa" in lane #4 contains crude extract from human cervical carcinoma cells (HeLa) known to be negative for TKO activity (12), and there is no competition with ISGF3 binding to the  $^{32}\text{P}$ -oligonucleotide probe (arrow).

Fig. 3 Examples of TKO resolution in 2-D gels. Positive images represent examples of purified whole cell extracts from C33a (3A) and ZR-75-1 (3B) cells stained with silver nitrate after electrophoresis as described: Immobilized ampholine gradient strips (pH3-10 non-linear) were obtained from Pharmacia and run under conditions outlined by the manufacturer. The strips were rehydrated overnight in a solution of 8M urea, 4% CHAPS, and 75 mM DTT, with bromophenol blue and 1% pharmalytes (pH 3-10). The strips were then placed onto an immobilon horizontal gel box and loaded with sample diluted in a 2X stock of 8 M urea, 4% CHAPS, 75 mM DTT, and 40 mM TRIS. The strips were run under silicon oil at 3500 volts



for 48 hr. The strips were then placed in equilibration buffer consisting of 4%SDS, 0.025 M TRIS pH 6.8, 30% glycerol, 1% iodoacetamide for 10 min, and loaded onto standard Laemmli SDS gels (15%) and run for 3 hrs. The stained spots indicated by arrows were eliminated when chromatographically enriched extract samples were depleted of TKO by incubations with a synthetic fragment of ISGF3 $\gamma$  as discussed in the above text.

(7) CONCLUSIONS: Analyses to date confirm that a negative regulator of transcriptional activation by IFN- $\alpha$ , which was identified in crude extracts of human breast cancer cells, corresponds in electrophoretic mobility to a ca. 20 kDa polypeptide purified from human cervical carcinoma cells and previously designated *TKO* (transcriptional knock-out factor). The correspondence was shown in direct comparisons of whole cell extracts purified by a series of column chromatographic steps and subjected to two-dimensional gel electrophoresis. Depletion tests with a synthetic fragment of ISGF3 $\gamma$  conjugated to sepharose-glutathione beads verified identity of the resolved 20 kDa polypeptide on 2D gels with TKO competitive binding activity. Sequence analysis of the highly purified material is in progress and we are currently accumulating purified material for inoculation of experimental animals. The aim in year 2 is to generate and pilot test monoclonal or polyclonal antibodies per original statement of work. In a second line of work, as originally proposed, tests of PRL signaling in three PRL-responsive human breast carcinoma lines (T47D, MCF-7 and BT-20) indicated that PRL-dependent STAT1 tyrosine phosphorylation was cell-dependent: different responses were observed in cells from well differentiated, estrogen-receptor-positive malignancies as compared to cells from a poorly differentiated malignancy. These initial findings suggest an inverse correlation of IFN and PRL effects and tentatively support our original hypothesis that changes in cytokine or growth factor signalling may parallel neoplastic evolution and pertain to individualization of patient treatment protocols.



#### (8) REFERENCES:

1. Curtis RE; Boice JD Jr; Stovall M; Bernstein L; et al.' Risk of leukemia after chemotherapy and radiation treatment for breast cancer N Engl J Med 326:1745-51, 1992
2. Kumar R; Korutla L; Zhang K Cell cycle-dependent modulation of alpha-interferon-inducible gene expression and activation of signaling components in Daudi cells. J Biol Chem 14:25437-41, 1994
3. Exley, R., Gordon, J., Nathan, P., Walker, L., and Clemens, M. J. Anti-proliferative effects of interferons on Daudi Burkitt lymphoma cells: induction of cell differentiation and loss of response to autocrine growth factors. Int J Cancer 40: 53-7, 1987.
4. Van den Berg HW; Leahey WJ; Lynch M; Clarke R; Nelson J Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br J Cancer 55:255-7, 1987

5. Genot, E., Sarfati, M., Sigaux, F., Petit-Koskas, E., Billard, C., Mathiot, C., Falcoff, E., Delespesse, G., and Kolb, J. - P. Effect of interferon-Alpha on the expression and release of the CD2 molecule in hairy cell leukemia. *Blood* 74: 2455-2463, 1989.
6. Borden EC; Balkwill FR; Preclinical and clinical studies of interferons and interferon inducers in breast cancer. *Cancer* 53(3 Suppl):783-9, 1984
7. Balkwill FR; Mowshowitz S; Seilman SS; Moodie EM; et. al. Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. *Cancer Res* 44:5249-55, 1984
8. Balkwill FR; Moodie EM Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. *Cancer Res* 1984 44:904-8
9. Hansen RM; Borden EC Current status of interferons in the treatment of cancer. *Oncology (Huntington)* 6:19-24, 1992
10. Antimi M; Majoli L; Minelli M; Stampino CG; et. al. A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease. *Tumori* 79:336-9, 1993
11. Buzdar AU; Hortobagyi GN; Kau SW; Smith TL; et. al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. *J Clin Oncol* 10:1540-6, 1992
12. Petricoin, E. 3rd, David, M., Fang, H., Grimley, P., Lerner, A. C., and Vande Pol, S. Human cancer cell lines express a negative transcriptional regulator of the interferon regulatory factor family of DNA binding proteins. *Mol Cell Biol.* 14: 1477-86, 1994.
13. Veals, S. A., Santa Maria, T. and Levy, D. E. Two Domains of ISGF3 $\gamma$  that Mediate protein-DNA and protein-protein interactions during transcription factor assembly contribute to DNA-binding specificity. *Mol. Cellular Biol.* 13: 196-206, 1993.
14. Tanaka N; Kawakami T; Taniguchi T; Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. *Mol Cell Biol* 13:4531-8, 1993
15. Shual, K., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Sadowski, H. B., Gilman, M. Z., and Darnell, J. E. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. *Nature.* 366: 580-3, 1993.
16. Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., Thierfelder, W. E., Kreider, B., and Silvennoinen, O. Signaling by the cytokine receptor superfamily: JAKs and STATs. *Trends Biochem Sci.* 19: 222-7, 1994.

17. Sadowski, H. B., Shuai, K., Darnell, J. E., Jr, and Gilman, M. Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. *Science* 261: 1739-44, 1993.
18. Rui H, Kirken RA, Farrar WL Activation of receptor-associated tyrosine kinase JAK2 by prolactin. *J Biol Chem*, 269; 5364-5368, 1994
19. David M; Petricoin EF 3rd; Igarashi K; Feldman GM; et. al. Prolactin activates the interferon-regulated p91 transcription factor and the Jak2 kinase by tyrosine phosphorylation. *Proc Natl Acad Sci U S A* 91:7174-8, 1994
20. Rui H, Lebrun J-J, Kirken RA, Kelly PA, Farrar WL JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. *Endocrinology*, 135: 1299-1306, 1994
21. Rui H, Erwin RA, Farrar WL, Larner AC, Grimley PM Interaction of prolactin and interferons  $\alpha/\beta$  on JAK/STAT signaling pathways in human breast cancer lines. Abstract, Tenth Annual Meeting of the International Society for Interferon and Cytokine Research, Baltimore, MD, 1995
22. Welsh CW, Nagasawa H; Prolactin and murine mammary tumorigenesis: a review. *Cancer Res* 37: 951-63, 1977
23. Bernstein L, Ross RK; Endogenous hormones and breast cancer risk. *Epidemiol Rev* 15: 48-65, 1993
24. Engel LW; Young NA; Tralka TS; Lippman ME; et. al. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. *Cancer Res* 38:3352-64, 1978

# Competitive inhibition of DNA binding complex formation (EMSA)





## Purified TKO / 2D gels

Fig - 3A C33a extract




Fig - 3B ZR 75-1 extract

